To see the other types of publications on this topic, follow the link: Tumore renale.
Journal articles on the topic 'Tumore renale'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Tumore renale.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Fandella, A., P. Checchin, L. Maccatrozzo, F. Merlo, L. Faggiano, D. Frezza, G. Cescon, R. Kirn, M. C. DA Mosto, and C. Marchiori. "Epistassi Segno Rivelatore Isolato Di Tumore Renale." Urologia Journal 58, no. 1 (February 1991): 105–6. http://dx.doi.org/10.1177/039156039105800124.
Full text
2
Lusardi, Paola. "Cardiotossicità da ormonoterapia nel tumore della prostata." Cardiologia Ambulatoriale, no. 3 (November 30, 2020): 195–97. http://dx.doi.org/10.17473/1971-6818-2020-3-10.
Full textAbstract:
Nel sesso maschile il tumore della prostata è il più rappresentato, ma la sopravvivenza a 10 anni dalla diagnosi è estremamente elevata (fino al 90%), sia per la diagnosi molto precoce attuata con le politiche di screening, sia per le elevate percentuali di malattia a rischio basso ed intermedio. La prognosi favorevole del tumore prostatico fa sì che il numero di comorbilità, quali dislipidemia, ipertensione, obesità, insufficienza renale cronica, cardiopatia ischemica e diabete, sia determinante sull’iter dei lungo sopravviventi. La terapia di deprivazione androgenica (ADT), che viene utilizzata nel setting terapeutico e palliativo, può essere considerata un fattore di rischio cardiovascolare aggiuntivo, in grado di accelerare i processi aterosclerotici sistemici e predisporre alla malattia coronarica e cerebrovascolare. Tutti i pazienti candidati o in trattamento con ADT devono pertanto essere valutati dal punto di vista cardiovascolare e metabolico e quindi stratificati per i fattori di rischio CV, ai fini di programmare la sorveglianza cardiologica e ridurre i danni potenziali dell’ADT.
3
Severino, R., V. Ramundo, L. Vuolo, C. Di Somma, G. Lombardi, A. Colao, S. Spiezia, and A. Faggiano. "Tumore bruno della Mandibola in un Paziente con Iperparatiroidismo Primitivo." Giornale di Clinica Nefrologica e Dialisi 22, no. 2 (January 24, 2018): 16–19. http://dx.doi.org/10.33393/gcnd.2010.1206.
Full textAbstract:
Gli Autori riportano un caso clinico in cui la diagnosi di tumore bruno dell'osso mascellare ha condotto alla definizione del processo patologico primitivo causato da un iperparatiroidismo sostenuto da adenoma primitivo della paratiroide. Il paziente, portatore di insufficienza renale cronica e nefrolitiasi ha eseguito biopsia e TC del mascellare, con diagnosi di tumore bruno associato ad altre aree di osteolisi a carico dell'osso mandibolare. Il profilo ematochimico ha rivelato una ipercalcemia con ipofosforemia associata a aumento del dosaggio sierico del paratormone, pertanto è stata eseguita una scintigrafia delle paratiroidi che ha mostrato la presenza di tessuto iperfunzionante in corrispondenza del terzo inferiore del lobo sinistro della tiroide. Il quadro eco-color-Doppler, ha confermato la presenza di un adenoma paratiroideo di 4,5 cm alla base del lobo sinistro della tiroide. Il paziente è stato sottoposto a terapia con cinacalcet in attesa dell'intervento chirurgico.
4
Pini, Giovannalberto, Domenico Veneziano, Vincenzo Altieri, Antonino Inferrera, Paolo Fornara, and Francesco Greco. "Nefrectomia Radicale Laparoendoscopic Single-site (LESS) nel Tumore Renale: Tecnica e Risultati Chirurgici Cosmetici e Valutazione del Dolore Postoperatorio." Urologia Journal 80, no. 22_suppl (April 2013): 16–23. http://dx.doi.org/10.5301/urologia.50000051.
Full text
5
Orellana, Fernanda Monteiro, Pablo Leonardo Traete, Victor Notari de Campos, Alan Rechamberg Ziroldo, and Luis Gustavo Morato de Toledo. "Clear - cell renal carcinoma: review of literature in pediatric population / Carcinoma renal de células-claras: revisão bibliográfica na população pediátrica." Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo 65, no. 1 (August 19, 2020): 1. http://dx.doi.org/10.26432/1809-3019.2020.65.017.
Full textAbstract:
ABSTRACT:Introduction: The first reports of renal tumors originated from the renal tubule epithelium date from 1855, Robin, and 1867, Waldeyer. However, at the same era, some pathologists wrong believed these tumors were originated from adrenal gland tissues due to the fat content of the tumor (hypernephroid tumor theory - origin above the kidney, 1894). The first diagnostic test for renal tumor was excretory urography. Over the years, with the emergence of ultrasonography (US), it has been replaced. Nowadays, after the US screening, all renal lesions should be evaluated, in a complementary way, with computed tomography (CT) - gold standard - in the pre-contrast, arterial, portal, nephrographic phases. This is necessary to characterize the presence of enhancement after contrast. A kidney injury that enhances more than 15 Housfield units (UH) is suspected of kidney cell cancer. There are different subtypes of renal tumors derived from various sites of the nephron. Clear cell Renal Cell Carcinoma (RCC) is one of the subtypes that originates from the renal cortex. It is a rare tumor in children. Objective: The aim of this chapter is to review de incidence, pathology, diagnosis and treatment in clear-cell renal carcinoma in pediatric population. Methods: The authors performed a literary review about clear-cell renal carcinoma in pediatric population using Pubmed Database and Campbell-Walsh Urology as source search.Keywords: Renal cell carcinoma, Tumor, Pediatrics, Kidney, Nefrectomy ResumoRESUMO:Introdução: Os primeiros relatos de tumores renais originados do epitélio do túbulo renal datam de 1855, Robin, e 1867, Waldeyer. Contudo, na mesma época, alguns patologistas acreditavam erroneamente que esses tumores provinham dos tecidos das glândulas supra-renais, devido ao teor de gordura do tumor (hypernephroid tumor theory – origem acima do rim, 1894). O primeiro teste diagnóstico para tumor renal foi a urografia excretora. Ao longo dos anos, com o surgimento da ultrassonografia, esse teste foi substituído. Atualmente, após a leitura da ultrassonografia, todas as lesões renais devem ser avaliadas, de forma complementar, com tomografia computadorizada (TC) – padrão ouro – nas fases pré-contraste, arterial, porta e nefrográfica. Isso é necessário para caracterizar a presença de melhora após contraste. Uma lesão renal que aumenta mais de 15 unidades Housfield (UH) é suspeita de câncer de células renais. Existem diferentes subtipos de tumores derivados de vários locais do néfron. O carcinoma de células renais de células claras (CCR) é um dos subtipos originários do córtex renal. É um tumor raro em crianças. Objetivo: O objetivo deste capítulo é revisar a incidência, a patologia, o diagnóstico e o tratamento do CCR na população pediátrica. Método: Os autores realizaram uma revisão literária sobre carcinoma renal de células claras em população pediátrica usando a base de dados PubMed e o livro Campbell-Walsh de Urologia como fonte de pesquisa.Palavras chave: Carcinoma de células renais, Tumor, Pediatria, Rim, Nefrectomia
6
Cruz, Antonio Cesar, Guilherme Lima, Isabella Pinheiro Litvin, and Paulo Eugênio M. A. Costa. "Nefrectomia parcial laparoscópica para tumor T2b em paciente com rim único: relato de caso." Anais da Faculdade de Medicina de Olinda 1, no. 3 (June 1, 2019): 42–44. http://dx.doi.org/10.56102/afmo.2019.68.
Full textAbstract:
Introdução: Para tumores T2, a maioria dos autores sugere a nefrectomia radical, porém, a literatura carece de relatos de nefrectomia para tumores T2b em pacientes com rim único. Relato de caso: RJAL, sexo masculino, 32 anos com tumor em rim esquerdo medindo 12 cm e agenesia renal direita. No pré-operatório apresentava função renal normal. Foi submetido à nefrectomia parcial laparoscópica em junho de 2016. Evoluiu com elevação da creatinina sérica e anúria, sendo então iniciada terapia renal substitutiva com hemodiálise. Após 20 dias, por apresentar normalização da função renal, optouse por suspender a mesma. O anatomopatológico revelou tratar-se de carcinoma de células renais. No momento, o paciente encontra-se fora de hemodiálise e com TC mostrando rim sem evidências de recidiva tumoral. Comentários: A nefrectomia parcial laparoscópica para tumores renais estádio T2b, é factível e pode ser indicada em casos selecionados como agenesia renal, com resultado oncológico eficaz e manutenção da função renal.
7
Delgado, Natalia, Jorge Forero, Rodolfo Varela, and Marino Cabrera F. "Radioablación por laparoscopia de masas renales pequeñas en pacientes octogenarios: técnica paso a paso." Revista Urología Colombiana / Colombian Urology Journal 27, no. 03 (May 29, 2018): 290–93. http://dx.doi.org/10.1055/s-0038-1656518.
Full textAbstract:
Introducción La cirugía preservadora de nefronas sigue siendo el gold standard de manejo en pacientes con tumores renales pequeños. La ablación por radiofrecuencia es una alternativa mínimamente invasiva con evidencia sustancial en efectividad en la erradicación tumoral completa. Objetivo Reportar el caso y la técnica paso a paso de la radioablación laparoscópica de un tumor renal en un centro de oncología de III nivel de Bogotá - Colombia. Materiales y Métodos Revisión de la historia clínica de un paciente con hallazgo incidental de una masa renal pequeña sometido a radioablación laparoscópica en un centro de oncología de III nivel de Bogotá. Conclusión La ablación por radiofrecuencia es una alternativa válida para el tratamiento de tumores renales pequeños, especialmente en adultos mayores y con alto riesgo quirúrgico, ofreciendo tasas de supervivencia libre de enfermedad comparables con la nefrectomía parcial.
8
Andino Guillén, Juan Pablo, and Leonardo Rayo Meza. "Tumores Renales Bilaterales: Reporte de caso." Revista Guatemalteca de Urología 9, no. 2 (February 23, 2022): 1–5. http://dx.doi.org/10.54212/27068048.v9i2.2.
Full textAbstract:
Objetivo: Reportar un caso de tumores renales bilaterales < 10 cm, limitado a las unidades renales sin datos de metástasis, revisando antecedentes y abordaje médico-quirúrgico. Presentación de Caso Clínico: Paciente masculino de 41 años de edad, sin comorbilidades presentes, con antecedentes de cirugía de tumor cerebral en fosa posterior en 2019. Acude con dolor lumbar de predominio derecho, al examen físico no se palpan masas. UroTC evidencia presencia de tumores renales bilaterales, masa derecha de 47 x 60 x 46 mm, masa izquierda de 51 x 68 x 59 mm, con realce al medio de contraste. Se realizo nefrectomía polar bilateral, con resultado histopatológico de carcinoma de células renales claras bilateral. Discusión: El abordaje de los tumores renales bilaterales es complejo, cuando las características por imagen sugieren un alto grado de malignidad se deberá realizar un abordaje hacia la resección del tumor en sus modalidades Nefrectomía Radical (NR) o nefrectomía parcial (NP). La evidencia es débil en cuanto al adecuado abordaje cuando las masas son bilaterales, debido a que solo se disponen revisiones de casos limitados en la literatura mundial. El riesgo en el transquirúrgico es elevado por las complicaciones que se pueden presentar con una alta presentación de sangrado que no se pueda controlar. En general la NP se considera únicamente en tumores > 4cm que se encuentren limitados a la unidad renal en condiciones especiales como pacientes monorrenos, tumores renales bilaterales o ERC en estadios avanzados.1 Conclusión: La cirugía conservadora de nefronas es un recurso útil, con buenos resultados quirúrgicos en pacientes con condiciones especiales, a pesar de encontrar hallazgos histopatológicos desfavorables con márgenes tomados la evidencia nos indica que no se incrementa el riesgo de metástasis o disminución del carcinoma de células claras, solo un 16% de los casos con márgenes quirúrgicos positivos tienen recurrencia local del tumor.2,3
9
Vasquez-Sullca, Roy R., Alfredo D. Balcazar-Reyes, Herman Yalta-Arce, and Luis A. Allemant-Mori. "Carcinoma renal con cuadro clínico de infección urinaria recurrente en paciente joven." Anales de la Facultad de Medicina 80, no. 1 (March 27, 2019): 60–63. http://dx.doi.org/10.15381/anales.v80i1.15427.
Full textAbstract:
El cáncer renal es una neoplasia con una tasa de incidencia de 4,4% por 100 000 habitantes a nivel mundial; el carcinoma de células renales representa el 90% de los tumores renales malignos. Las infecciones urinarias recurrentes tienen una prevalencia del 19% y constituyen infecciones de al menos dos episodios en seis meses, o al menos tres episodios en un año. Presentamos el caso de una paciente mujer de 25 años que presentó cuadros de infecciones urinarias recurrentes y que en un estudio tomográfico se evidenció una tumoración renal izquierda. Se le realizó nefrectomía radical cuya pieza operatoria confirmó diagnóstico patológico de carcinoma renal de células clara. En pacientes jóvenes el carcinoma renal es una tumoración aún más rara, que representa 8,7% del total de pacientes diagnosticados de cáncer renal. Se debe promover en la consulta médica la sospecha clínica a mujeres jóvenes con infecciones urinarias recurrentes solicitando exámenes de imagen, con la finalidad de garantizar un temprano diagnóstico y tratamiento adecuado si se tratara de un tumor renal.
10
Tillyashaykhov, Mirzagaleb, Elena Boyko, and Shakhnoza Jumaniyazova. "EXTRATUMOR MICROENVIRONMENT IN RENAL CELL CARCINOMA." UZBEK MEDICAL JOURNAL 2, no. 4 (April 30, 2021): 5–12. http://dx.doi.org/10.26739/2181-0664-2021-4-1.
Full textAbstract:
The review is focused on studying the immunosuppressive mechanisms acting in the microenvironment of renal cell carcinoma tumors. The report contains a collection of basic literature materials on the study of tumor growth factors that boost tumor cell proliferation and metastasis. The tumor microenvironment (TME) limits the immune surveillance of tumor-associated antigens and the effectiveness of immune checkpoint inhibitors. Although renal cell carcinoma is one of several tumor types sensitive to immune checkpoint inhibitors, the efficacy of these agents is likely to be limited by different tumor-infiltrating myeloid cells of bone marrow that make up the TME. Several strategies aimed at eliminating the onset of these cells in tumor tissue or neutralizing their immunosuppressive function have shown encouraging results in animal tumor models and clinical trials.Keywords: cytotoxic T lymphocytes (CTL), immune checkpoint inhibitor (ICI), tumor microenvironment (MEV), myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), renal cell carcinoma (RCC), tumor-associated macrophages (TAM), vascular endothelial growth factor (VEGF)
11
Pérez Reyes, M., C. Rodríguez Silva, A. Cabello Burgos, and J. Santoyo Santoyo. "Metastatic recidives in abdominal wall in renal cell carcinoma." Cirugía Andaluza 30, no. 4 (November 8, 2019): 526–29. http://dx.doi.org/10.37351/2019304.15.
Full textAbstract:
Resumen El cáncer de células renales es responsable de un 2-3% de todos los tumores malignos en el adulto. El carcinoma renal es la lesión sólida más frecuente en el riñón y representa aproximadamente un 90% de todos los tumores renales malignos. Aproximadamente del 25% al 30% de los pacientes se presentan como enfermedad diseminada en el momento del diagnóstico. La localización más frecuente de las metástasis es en los pulmones. Presentamos un paciente intervenido en 2011 de nefrectomía radical derecha laparoscópica por cáncer de células renales estadio II con grado de Furhmann 2-3. Se deriva a consulta de Cirugía por hallazgo incidental siete años después en TAC abdominal de control, de una lesión compatible con tumor desmoide de 3 cm en recto abdominal derecho, localizado en la zona de la cicatriz previa. Se interviene de forma programada, realizándose exéresis de dicha lesión, con resultado de anatomía patológica de metástasis de carcinoma de células renales. El postoperatorio evolucionó sin incidencias. El diagnóstico suele aparecer como hallazgo incidental durante el seguimiento del cáncer renal por ello es importante contemplar la posibilidad de localización atípica ya que podrá influir en un diagnóstico y tratamiento precoz y con ello modificar el curso evolutivo de la enfermedad. El manejo debe ser individualizado.
12
Longo Rodas, Angel Rodrigo, Hugo Barbales, Ricardo Tercero, Gustavo González, Marco Antonio Ortiz, and Angel Valdez. "Tumor Renal Bilateral: Nefrectomía Parcial Bilateral en un Tiempo Quirúrgico: Reporte de Caso." Revista Guatemalteca de Urología 10, no. 2 (February 15, 2023): 20–24. http://dx.doi.org/10.54212/27068048.v10i2.136.
Full textAbstract:
Objetivo: Reportar caso de nefrectomía parcial bilateral con adecuada evolución, exponiendo abordaje médico y quirúrgico. Presentación de caso clínico: Paciente masculino de 70 años, quien es evaluado y se evidencia presencia de masas sólidas renales bilaterales, no se evidencia invasión vascular, ni adenopatías. Dichas lesiones se encuentran limitadas al parénquima renal, por lo que paciente pasa sala de operaciones para realización de nefrectomía parcial bilateral. Pieza quirúrgica en cortes histológicos corresponde a neoplasia con patrón alveolar compuesta por nidos celulares (Carcinoma de células renales, variedad de células claras). Paciente con adecuada evolución post operatoria con buen pronóstico. Discusión: El carcinoma de células renales corresponde un 85-90% de los tumores renales sólidos, estos se presentan en forma bilateral en un 1-4% de los pacientes. El tumor bilateral puede ser sincrónico o asincrónico, los sincrónicos se presentan de forma simultánea o hasta un año luego de diagnosticada la primera lesión y considerando a los que aparecen más tarde como metacrónicos o asincrónicos. El abordaje de dichas lesiones es complejo, la evidencia científica es escasa respecto al abordaje idóneo en tumores renales bilaterales debido a los pocos casos reportados a nivel mundial. Conclusión: La nefrectomía parcial bilateral es un procedimiento quirúrgico con pronostico favorable para los pacientes, conservando la función renal con el fin de proteger la calidad de vida. (1-3)
13
Galluzzo, Maria Laura, Maria T. Garcia de Davila, and Gordan M. Vujanić. "A Composite Renal Tumor: Metanephric Adenofibroma, Wilms Tumor, and Renal Cell Carcinoma: A Missing Link?" Pediatric and Developmental Pathology 15, no. 1 (January 2012): 65–70. http://dx.doi.org/10.2350/11-03-1007-cr.1.
Full textAbstract:
A coexistence of different renal tumors has rarely been reported. The most commonly described association is of Wilms tumor and renal cell carcinoma. Metanephric adenofibroma has also been associated with Wilms tumor or papillary renal cell carcinoma. Another reported association is metanephric adenoma and papillary renal cell carcinoma with sarcomatoid dedifferentiation. Herein we describe a complex renal tumor containing areas of metanephric adenofibroma, Wilms tumor, and undifferentiated renal cell carcinoma in a previously healthy 18-year-old boy. The tumor showed histologic and immunohistochemical features of these 3 different tumors, offering additional support to the view that these 3 tumors are related.
14
Ricketts, Reva, Pheroze Tamboli, Bogdan Czerniak, and Charles C. Guo. "Tumor-to-Tumor Metastasis: Report of 2 Cases of Metastatic Carcinoma to Angiomyolipoma of the Kidney." Archives of Pathology & Laboratory Medicine 132, no. 6 (June 1, 2008): 1016–20. http://dx.doi.org/10.5858/2008-132-1016-tmroco.
Full textAbstract:
Abstract Tumor-to-tumor metastasis is a rare phenomenon. Renal cell carcinoma is the most common recipient of tumor-to-tumor metastasis in malignant tumors. However, renal angiomyolipoma has not been reported to be a recipient. Here we report 2 cases of tumor-to-tumor metastasis to renal angiomyolipoma. In one case, the donor tumor originated from neuroendocrine carcinoma of the pancreas, and in the other case the donor tumor was from adenocarcinoma of the lung. The donor tumors showed morphologic features that did not easily fit into renal angiomyolipoma, and they also demonstrated patterns of immunoreactivity consistent with the primary tumors rather than with renal angiomyolipoma. To our knowledge, these are the first reported cases of tumor-to-tumor metastasis to renal angiomyolipoma. An awareness of this phenomenon is important to avoid an incorrect diagnosis when encountering unusual morphologic features in renal angiomyolipoma.
15
Liu, Guangxiang, Tingsheng Lin, Qing Zhang, Shengjie Zhang, Changwei Ji, Shiwei Zhang, and Hongqian Guo. "Hyaluronic Acid-IR780 Nanoparticles for Photothermal Ablation in Orthotopic Renal Cancer." Journal of Nanomaterials 2020 (April 16, 2020): 1–8. http://dx.doi.org/10.1155/2020/2421971.
Full textAbstract:
Renal cancer is one of the most common malignancies in urological tumors; it is necessary to develop a noninvasive and highly targeted thermal ablation method for the treatment of renal tumors. IR780 has been shown to be an effective photothermal agent for tumor thermal ablation. This study was designed to explore the feasibility of applying hyaluronic acid-IR780 nanoparticles (HA-IR780 NPs) for targeted thermal ablation of renal tumors using an in situ renal tumor model. The size of the nanoparticles was 172±8.2 nm; it showed a stable spherical nanostructure with good monodispersity. HA-IR780 NPs showed high photothermal efficiency, with the 20 μg/mL HA-IR780 NPs showing a maximum temperature increase of 24.5°C with 6 min of 808 nm laser irradiation. NIR imaging showed that the nanoparticles exhibited targeted accumulation in renal tumor tissues. The treatment efficacy of the HA-IR780 NPs showed that renal tumors treated with the HA-IR780 NPs and laser irradiation were effectively ablated. Our results showed that the HA-IR780 nanoparticles that mediated the photothermal effect could generate tumor-specific heat for the destruction of a renal tumor in a minimally invasive way, which provides a novel strategy for thermal ablation of renal tumors.
16
Vargas Rocha, Vladimir Erik, Juan Carlos Freire Guffanti, and Patricia Segales-Rojas. "Experiencia en Nefrectomía Parcial y Enucleación de Tumor Renal Laparoscópico “Zero Isquemia”, en Cochabamba, Bolivia." Gaceta Medica Boliviana 45, no. 1 (June 20, 2022): 23–28. http://dx.doi.org/10.47993/gmb.v45i1.367.
Full textAbstract:
Antecedentes: El manejo quirúrgico de los tumores renales pequeños es la cirugía conservadora de nefronas, este tipo de manejo se reservaba para pacientes seleccionados, con riñón solitario, enfermedad renal crónica o tumores bilaterales. La evidencia sugiere que la nefrectomía parcial laparoscópica es equivalente en términos de resultados oncológicos y superior en las mediciones de calidad de vida comparada al abordaje abierto.
Objetivos: Determinar los resultados oncológicos en cuanto a bordes libres del tumor y complicaciones quirúrgicas en pacientes sometidos a nefrectomía parcial y enucleación de tumor renal laparoscópico “Zero isquemia”.
Metodología: Estudio retrospectivo, observacional, y comparativo, que fueron sometidos a nefrectomía parcial laparoscópica, se agruparon en dos grupos: Grupo I: nefrectomía parcial y Grupo II: enucleación, se analizaron: tamaño y localización del tumor, RENAL score, tiempo quirúrgico, sangrado, días de estancia, complicaciones y reporte histopatológico.
Resultados: Se evaluaron 17 pacientes, 3 fueron excluidos por terminar en cirugía radical, 6 parciales (Grupo I) y 8 enucleaciones (Grupo II). Edad promedio de 45.7 (± 8.6) vs 51.2 (± 6.3) años. Tamaño del tumor 7.8 (2.5-10) vs 3.2 (1-5.7) cm, El RENAL score en global de todos los pacientes fue de baja a moderada. Hubo diferencias a favor del grupo II (enucleación) en cuanto a tiempo quirúrgico y sangrado transoperatorio, en cuanto a los bordes quirúrgicos, se tuvo 2 (14.2%) casos con bordes positivos 1 para cada abordaje, los cuales se mantienen en vigilancia estrecha.
Conclusiones: el abordaje laparoscópico es una opción equiparable al abierto, se obtuvieron iguales resultados en cuanto a control oncológico en relación a bordes libres y con menos complicaciones.
17
Stojanovic, Nebojsa, Ivan Ignjatovic, Milos Kostov, Zaklina Mijovic, Sladjana Zivkovic, and Branko Kosevic. "Giant renal oncocytoma." Vojnosanitetski pregled 70, no. 1 (2013): 68–71. http://dx.doi.org/10.2298/vsp1301068s.
Full textAbstract:
Background. Renal onkocytoma is a distinctive benign tumor derived from epithelial cells of the distal renal tubules. These tumors are often clinically asymptomatic, diagnosed accidentally and difficult to distinguish from renal cell carcinoma. Case report. We presented a giant renal onkocytoma in a man aged 64, without any signs or symptoms of the urogenital system disorder. The preoperative diagnosis described the tumor mass of the right kidney, size 16 x 14 cm, and indicated a malignant tumor of kidney. The patient underwent radical nephrectomy. The tumor was encapsulated at the intersection with the characteristic central hyaline scar. Microscopically, it was built of uniform polygonal cells with abundant eosinophilic cytoplasm. Immunohystochemiclly, tumor cells were immunoreactive to CK AE1/AE3 and CD 117, but showed negative immunoreactivity to CK 7, RCC marker and Vimentin. Conclusion. Giant renal oncocytomas are rare tumors with benign clinical course. As a rule, they are discovered by accident. Clinical differentiation from malignant tumors of the kidney is not possible. They are treated surgically, mainly by radical nephrectomy. A definitive diagnosis is made only by histopathological examination of tumors using immunohistochemical marker panels.
18
Souza, Salena Silva, Bruno Hállan Meneses Dias, Alexandre Sabóia Leitão Júnior, Rommel Prata Regadas, João Batista Gadelha de Cerqueira, and Ricardo Reges Maia de Oliveira. "Relato de caso: Schwannoma de origem renal." Revista de Medicina da UFC 61, no. 1 (February 19, 2021): 1–4. http://dx.doi.org/10.20513/2447-6595.2021v61n1e43233p1-4.
Full textAbstract:
Schwannomas são tumores que se originam das células de Schawnn. Normalmente se localizam na cabeça, pescoço e membros, mas podem ocorrer em qualquer parte do corpo onde existam nervos mielinizados. O acometimento renal é raro, com poucos casos descritos na literatura. Seu diagnóstico pré-operatório é difícil, visto que se baseiam apenas numa apresentação clínica inespecífica e em características radiológicas limitadas. Embora alguns achados na Ressonância Nuclear Magnética (RNM) possam levantar a suspeição do diagnóstico, esses tumores são frequentemente confundidos com Carcinoma de Células Renais, tendo a ressecção cirúrgica como tratamento padrão. Comumente requerem um diagnóstico patológico. E apesar da maior parte dos casos exibir comportamento benigno, a degeneração maligna pode ocorrer. Nós trazemos o relato de um caso de tumor no hilo renal direito, submetido a ressecção cirúrgica, cujo diagnóstico de Schwannoma renal foi confirmado histologicamente.
19
Bartholow, Tanner, and Anil Parwani. "Renal Primitive Neuroectodermal Tumors." Archives of Pathology & Laboratory Medicine 136, no. 6 (June 1, 2012): 686–90. http://dx.doi.org/10.5858/arpa.2011-0104-rs.
Full textAbstract:
Primitive neuroectodermal tumors exist as a part of the Ewing sarcoma/primitive neuroectodermal tumor family. These tumors most commonly arise in the chest wall and paraspinal regions; cases with a renal origin are rare entities, but have become increasingly reported in recent years. Although such cases occur across a wide age distribution, the average age for a patient with a renal primitive neuroectodermal tumor is the mid- to late 20s, with both males and females susceptible. Histologically, these tumors are characterized by pseudorosettes. Immunohistochemically, CD99 is an important diagnostic marker. Clinically, these are aggressive tumors, with an average 5-year disease-free survival rate of only 45% to 55%. Given that renal primitive neuroectodermal tumor bears many similarities to other renal tumors, it is important to review the histologic features, immunostaining profile, and genetic abnormalities that can be used for its correct diagnosis.
20
Sriram, Renuka, Jeremy Gordon, Celine Baligand, Fayyaz Ahamed, Justin Delos Santos, Hecong Qin, Robert Bok, et al. "Non-Invasive Assessment of Lactate Production and Compartmentalization in Renal Cell Carcinomas Using Hyperpolarized 13C Pyruvate MRI." Cancers 10, no. 9 (September 5, 2018): 313. http://dx.doi.org/10.3390/cancers10090313.
Full textAbstract:
Optimal treatment selection for localized renal tumors is challenging due to their variable biological behavior and limited ability to pre-operatively assess their aggressiveness. We investigated hyperpolarized (HP) 13C pyruvate MRI to noninvasively assess tumor lactate production and compartmentalization, which are strongly associated with renal tumor aggressiveness. Orthotopic tumors were created in mice using human renal cell carcinoma (RCC) lines (A498, 786-O, UOK262) with varying expression of lactate dehydrogenase A (LDHA) which catalyzes the pyruvate-to-lactate conversion, and varying expression of monocarboxylate transporter 4 (MCT4) which mediates lactate export out of the cells. Dynamic HP 13C pyruvate MRI showed that the A498 tumors had significantly higher 13C pyruvate-to-lactate conversion than the UOK262 and 786-O tumors, corresponding to higher A498 tumor LDHA expression. Additionally, diffusion-weighted HP 13C pyruvate MRI showed that the A498 tumors had significantly higher 13C lactate apparent diffusion coefficients compared to 786-O tumors, with corresponding higher MCT4 expression, which likely reflects more rapid lactate export in the A498 tumors. Our data demonstrate the feasibility of HP 13C pyruvate MRI to inform on tumor lactate production and compartmentalization, and provide the scientific premise for future clinical investigation into the utility of this technique to noninvasively interrogate renal tumor aggressiveness and to guide treatment selection.
21
Vela Mollinedo, Roberto Alejandro, Hugo Roberto Arriaga Morales, and Carlos Francisco Figueroa Lemus. "Nefrectomía por Trauma en Riñón Supernumerario." Revista Guatemalteca de Urología 4, no. 1 (December 31, 2017): 28–31. http://dx.doi.org/10.54212/27068048.v4i1.91.
Full textAbstract:
Una anomalía renal preexistente aumenta la probabilidad de lesión renal después del traumatismo.
Hidronefrosis secundaria a una anomalía de la unión ureteropiélica, cálculos renales, quistes y tumores son las entidades descritas con más frecuencia que pueden complicar una lesión renal leve.
Generalmente se descubren por hallazgos radiológicos, en el estudio de complicaciones producto de infección, litiasis, tumores, procesos obstructivos, etc. El tratamiento será el de los procesos acompañantes, pero generalmente conlleva a nefroctomía.
22
Goyal, Rajen, Elizabeth Gersbach, Ximing J. Yang, and Stephen M. Rohan. "Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine." Archives of Pathology & Laboratory Medicine 137, no. 4 (April 1, 2013): 467–80. http://dx.doi.org/10.5858/arpa.2012-0085-ra.
Full textAbstract:
Context.—The World Health Organization classification of renal tumors synthesizes morphologic, immunohistochemical, and molecular findings to define more than 40 tumor types. Of these, clear cell (conventional) renal cell carcinoma is the most common malignant tumor in adults and—with the exception of some rare tumors—the most deadly. The diagnosis of clear cell renal cell carcinoma on morphologic grounds alone is generally straightforward, but challenging cases are not infrequent. A misdiagnosis of clear cell renal cell carcinoma has clinical consequences, particularly in the current era of targeted therapies. Objective.—To highlight morphologic mimics of clear cell renal cell carcinoma and provide strategies to help differentiate clear cell renal cell carcinoma from other renal tumors and lesions. The role of the pathologist in guiding treatment for renal malignancies will be emphasized to stress the importance of proper tumor classification in patient management. Data Sources.—Published literature and personal experience. Conclusions.—In challenging cases, submission of additional tissue is often an inexpensive and effective way to facilitate a correct diagnosis. If immunohistochemical stains are to be used, it is best to use a panel of markers, as no one marker is specific for a given renal tumor subtype. Selection of limited markers, based on a specific differential diagnosis, can be as useful as a large panel in reaching a definitive diagnosis. For renal tumors, both the presence and absence of immunoreactivity and the pattern of labeling (membranous, cytoplasmic, diffuse, focal) are important when interpreting the results of immunohistochemical stains.
23
Toei, Hiroshi, Xixi Zhang, Kuniaki Seyama, Daisuke Yashiro, Yoshiki Kuwatsuru, and Ryohei Kuwatsuru. "Prophylactic renal artery embolization before pregnancy in patients with lymphangioleiomyomatosis and renal angiomyolipoma." Journal of International Medical Research 50, no. 9 (September 2022): 030006052211238. http://dx.doi.org/10.1177/03000605221123897.
Full textAbstract:
Objective Pregnant patients with lymphangioleiomyomatosis (LAM) and renal angiomyolipomas (AMLs) require care for both renal AMLs and pulmonary dysfunction because AMLs can grow and rupture during pregnancy, potentially causing hemorrhagic shock and fetal death. This study examined whether prophylactic transcatheter arterial embolization (TAE) could prevent the pregnancy-associated growth and rupture of renal AMLs in patients with LAM. Methods This retrospective study included five women with 14 renal AMLs (initial diameter, ≥2 cm) first encountered between September 2010 and August 2015 who subsequently became pregnant. Seven tumors in five patients were embolized, and seven tumors in two patients were not treated. Changes in the volume of each tumor were evaluated. Results Untreated tumors were much more likely to grow than embolized tumors both during pregnancy (100% vs. 0%) and at the first follow-up visit after delivery (100% vs. 14%). One untreated hypervascular tumor grew rapidly during pregnancy to 409% of the pretreatment volume. No tumor ruptured. Conclusions Prophylactic pre-pregnancy TAE decreased the growth and bleeding of renal AMLs during pregnancy in patients with LAM. TAE can be recommended for hypervascular tumors before pregnancy regardless of the size of the aneurysm.
24
Gupta, Sahil, Kaustav Majumder, Anurag Chahal, Ashish K. Saini, and Arjun Gupta. "Management of Primitive Neuroectodermal Tumor of the Kidney with Inferior Vena Cava Thrombus." Current Urology 9, no. 1 (2015): 47–50. http://dx.doi.org/10.1159/000442851.
Full textAbstract:
Primitive neuroectodermal tumors (PNET) are an aggressive group of small round cell tumors usually arising in the nervous system and affecting children. They have a tendency for local invasion, distant spread and formation of tumor thrombi. The kidney is a rare primary location for these tumors. Outcomes are frequently poor due to late diagnosis (Wilms tumor is a more common tumor in this population) and early spread. Immunohistochemistry is invaluable in making the diagnosis of PNET. We report a case of a primary renal PNET with extensive tumor thrombus into the inferior vena cava, and lung metastasis in a pediatric patient, and its successful management. Our 14-year-old patient with renal PNET was managed with radical nephrectomy, thrombectomy and chemotherapy and remains disease free to date. The diagnosis of renal PNETs should be considered in young adult patients who present with aggressive renal masses at initial presentations. Despite its aggressive nature, good outcomes can be achieved by a multimodality therapeutic strategy.
25
Abdelsalam, Mohamed E., Sharjeel H. Sabir, Samuel B. Kusin, Surena F. Matin, Christopher G. Wood, Jose A. Karam, and Kamran Ahrar. "Incidental renal tumors in cancer survivors: Minimally invasive management by image-guided thermal ablation." Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016): 258. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.258.
Full textAbstract:
258 Background: To investigate presentation, management and outcome of renal tumors in patients with prior or current history of cancer. Methods: A retrospective review of a database for patients undergoing ablation of renal tumors between January 2012 and June 2014 was performed. For each patient , the following was recorded: Prior or current history of cancer (other than renal cell carcinoma), histology of primary tumor, status of primary cancer (remission or under therapy), size of the renal tumor, thermal ablation technology , complications of ablation, development of metastases from renal tumor, deceased or alive , cause of death and the length of follow up. Results: Ninety five renal ablation procedures were performed in 91 patients between January 2012 and June 2014. Of this subset, 37 patients (27 male and 10 females) with average age 63 years (Age range 53-85 Years) had prior or current history of malignancy (6 patients had more than one primary cancer) other than renal tumor including Prostate(6), colorectal (4), Breast (4) lymphoma (3) and others (20). All renal tumors were discovered incidentally, none of the patients had symptoms related to renal tumors. Twenty four patients were in remission and 13 patients were undergoing therapy for their primary malignancy at the time of ablation. Ablation was performed using radiofrequency (n = 30) or cryoablation (n = 9) for 39 renal lesions with average size of 2.4cm (Range 1.1 to 4 cm). After average of 20 months (range 5-35 months) of observation 34 patients (92%) were still alive. Three patients died of their primary cancer. None of the patients developed complication from the procedure, 1 patient had recurrence after 6 month; for which renal ablation was performed. None of the patients developed metastatic disease from or died of renal cell carcinoma. Conclusions: Staging workup and surveillance imaging studies in cancer patients can lead to incidental detection of primary renal tumors. Minimally invasive therapy with image guided radiofrequency ablation or cryotherapy is feasible, safe and effective. Image guided ablation has no discernable impact on the course of therapy for the primary tumor. Furthermore, it has minimal to no morbidity for patients in remission.
26
Müller, Petr. "Renal artery pseudoaneurysm after open renal enucleation." Urologie pro praxi 23, Urologie pro praxi 1 (March 16, 2022): 48–50. http://dx.doi.org/10.36290/uro.2020.052.
Full text
27
Siudak, Krystyna, Lena Stallenberger, Christiane Herden, and Julia Vienenkötter. "Renal neoplasia in horses – a retrospective study." Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere 45, no. 05 (2017): 290–95. http://dx.doi.org/10.15653/tpg-161091.
Full textAbstract:
SummaryObjective: Being confronted with a case series of renal neoplasia in several horses which was in striking divergence to literature data, we recognized the need of a retrospective study to assess the presence of renal neoplasms in horses. Material and methods: Anamnestic animal data, necropsy findings and results of histological and immuno histochemical examinations from 2010 through 2015 were collected and evaluated regarding renal neoplasia. Results: Data from postmortem examinations of 1069 horses revealed 20 horses with renal tumors constituting a prevalence of 1.87 %. Primary renal neoplasms built the majority of cases (n = 15; 75 % of total renal neoplasms) and comprised nine renal carcinomas, four renal adenomas, one renal neuroendocrine tumor and a single nephroblastoma. Among the five secondary renal neoplasms lymphosarcoma was most common (3/5). Remaining metastatic tumors comprised one melanoma and one hemangiosarcoma. No breed or sex predilections were noticeable. Except for the case of nephroblastoma in a stillborn foal, all horses presenting with renal tumors were more than 10 years of age, often older than 20 years. Anamnestic data and clinical symptoms were inconclusive and not assigned to renal disease in most cases. Merely one horse with renal carcinoma presented with renal insufficiency and two horses showed signs of shock due to severe bleeding after tumor capsule rupture in renal carcinoma. Conclusion and clinical relevance: Renal tumors occur more often than anticipated, especially in older horses. Contradictorily to the literature, primary renal tumors significantly outnumbered secondary neoplasms in this study.
28
Bussolati, Benedetta, Alessia Brossa, and Giovanni Camussi. "Resident Stem Cells and Renal Carcinoma." International Journal of Nephrology 2011 (2011): 1–6. http://dx.doi.org/10.4061/2011/286985.
Full textAbstract:
According to the cancer stem cell hypothesis tumors are maintained by a cancer stem cell population which is able to initiate and maintain tumors. Tumor-initiating stem cells display stem or progenitor cell properties such as self-renewal and capacity to re-establish tumors that recapitulate the tumor of origin. In this paper, we discuss data relative to the presence of cancer stem cells in human renal carcinoma and their possible origin from normal resident stem cells. The cancer stem cells identified in human renal carcinomas are not derived from the normal CD133+progenitors of the kidney, but rather from a more undifferentiated population that retains a mesenchymal phenotype. This population is able to self-renewal, clonogenicity, and in vivo tumor initiation. Moreover, they retain pluripotent differentiation capability, as they can generate not only the epithelial component of the tumor, but also tumor endothelial cells. This suggests that renal cancer stem cells may contribute to the intratumor vasculogenesis.
29
Lambis Ricardo, Jorge, Sandra Herrera Lomónaco, Gabriel De León Manotas, Carlos Ballestas Almario, Stephany Montenegro Castañeda, Aura González Peralta, and Rina Barrios Barreto. "Carcinoma de células renales cromófobas, en paciente joven, tratada con nefrectomía parcial." Revista Ciencias Biomédicas 6, no. 1 (November 27, 2020): 160–64. http://dx.doi.org/10.32997/rcb-2015-2997.
Full textAbstract:
Introducción: el carcinoma de células renales representa el 90% de las neoplasias malignas renales, siendo una de las variantes histológicas, el carcinoma de células renales cromófobas (CCRC). Su presentación clínica es inespecífica y generalmente es un tumor bien circunscrito, más frecuente en la sexta década de la vida y de buen pronóstico.Caso clínico: paciente femenina de 23 años con cuadro de hematuria intermitente más síntomas irritativos. Estudios imagenológicos mostraron masa nodular en polo inferior izquierdo de 33 x 36 mm de diámetro. Biopsia percutánea guiada por imagen, reportó CCRC. Se realizó nefrectomía parcial, con preservación del parénquima sano. La paciente ha presentado evolución satisfactoria.Conclusión: el CCRC es un subtipo histológico poco frecuente de carcinoma renal. Es importante a detección precoz y su presentación es en un amplio rango de edad, por lo que se sugiere sospecharlo en pacientes jóvenes con masa renal. Siendo un tumor bien delimitado, algunos casos pueden tratarse con nefrectomía parcial para conservar la función renal. Rev.cienc.biomed. 2015;6(1):160-164
30
Takekawa, Shoici D., Hideo Sakuma, Maiko Baba, Shouei Sai, Yoshikei Miura, Kenji Kawakura, Takehiko Abe, et al. "Sarcomatoid Renal Cell Carcinoma Diagnosed by Percutaneous Needle Biopsy." Jurnal Radiologi Indonesia 3, no. 1 (July 1, 2017): 17–21. http://dx.doi.org/10.33748/jradidn.v3i1.61.
Full textAbstract:
A 56-year-old man presented with discomfort in the abdomen and backache. He lost his body weight by 10 Kg in 6 months.A large retroperitoneal mass was found in addition to the right renal mass.It seemed necessary to exclude additional tumor in theretroperitoneum.Abdominal CT with and without contrast enhancement showed Tumors in the right kidney and giant tumors in the retroperitoneum. Percutaneous core needle biopsy of the retroperitoneal tumor and renal tumor was carried out under CT control.Pathological study revealedsarcomatoid renal cell carcinoma in the retroperitoneal mass, but mostly fibrous tissue in the renal mass.Final diagnosis was sarcomatoid renal cell carcinoma with retroperitoneal extension. This type of renal cell carcinoma is noted to have very poor prognosis in the literature. Our case was also poor in prognosis, and the patient expired three months after the diagnosis was established.
31
Nyman, U., J. Oldbring, and P. Aspelin. "CT of Carcinoma of the Renal Pelvis." Acta Radiologica 33, no. 1 (January 1992): 31–38. http://dx.doi.org/10.1177/028418519203300107.
Full textAbstract:
CT in 28 histologically proven carcinomas of the renal pelvis (pTa-2, n = 12; pT3–4, n = 16) in 26 patients was evaluated retrospectively. Twenty-four of 28 tumors could be identified at CT, 17/28 at urography, and 12/14 at retrograde pyelography. Nineteen tumors appeared as a discrete intrapelvic mass with an attenuation close to that of the kidney on noncontrast scans. There was slight to moderate enhancement of the tumors following i.v. contrast medium injection but they appeared hypodense relative to the renal parenchyma. Five tumors caused only a diffuse obliteration of the renal sinus. Criteria to define peripelvic tumor growth are proposed, i.e. tumors obliterating fat planes or abutting of renal parenchyma should not be regarded as signs of extrapelvic extension, while inhomogeneous attenuation of peripelvic fat and renal parenchyma (in the absence of other explanation) should, or if the tumor mass is seen interdigitizing with surrounding structures. Thickening of Gerota's fascia or septa in the perirenal space are unspecific findings. With CT we were able to differentiate tumors confined to the renal pelvic wall from those with more advanced disease including metastases in 22 of 26 patients.
32
Giardini, Anna, Marcella Ottonello, Carlo Pasetti, Debora Pain, and Ines Giorgi. "Cosa voglio fare alla fine della vita? Consapevolezza della malattia, conoscenza delle procedure cliniche e delle direttive anticipate in pazienti con malattie croniche progressive / What do I want to be done at end-of-life? Disease awareness, knowledge of clinical procedures and of advanced directives in patients with chronic progressive diseases." Medicina e Morale 67, no. 1 (March 23, 2018): 11–24. http://dx.doi.org/10.4081/mem.2018.525.
Full textAbstract:
Scopo del nostro studio osservazionale cross-sectional è di studiare la consapevolezza di malattia, la conoscenza delle procedure cliniche e delle dichiarazioni anticipate di trattamento in pazienti italiani affetti da patologie croniche progressive. Metodo. Sono stati valutati 115 soggetti (23 con Sclerosi Laterale Amiotrofica – SLA; 30 con Scompenso Cardiaco Cronico – SCC; 32 con Insufficienza Renale Cronica – IRC; 30 con Tumore Avanzato –TA) su: conoscenza sui temi della salute, diritto ad essere informati, significato delle Direttive Anticipate (DA) e delle Dichiarazioni Anticipate di Trattamento (DAT). Risultati. 86% dei pazienti hanno evidenziato il diritto di conoscere diagnosi e prognosi e di essere informati sull’evoluzione di malattia. Molti pazienti non conoscevano il significato di procedura invasiva (52%) o di trattamento aggressivo (81%). Il 72% non conosceva il significato di DA e di DAT; il 94% riteneva che le DA o le DAT potessero parzialmente o totalmente garantire il desiderio del paziente di prendere parte alle decisioni sulla gestione del fine vita. Una volta informati sul significato delle AD (vincolanti) e delle DAT (non vincolanti) I pazienti con SLA preferivano la scelta di direttive vincolanti rispetto ai pazienti con TA e con SCC (SLA vs SCC p=.005; SLA vs TA p=.001). I pazienti con IRC preferivano direttive vincolanti rispetto ai pazienti con SCC (p=.02). Conclusioni. Deve essere parte integrante nella pratica clinica l’informare e il guidare il paziente dal momento della diagnosi fino alle fasi ultime di vita. ---------- Introduction. Many steps forward within the legal field to facilitate end-of-life communication have been taken, but Mediterranean countries can be considered as a step back. Aim of our observational cross-sectional study is to observe disease awareness, knowledge of clinical procedures and of advanced directives in patients with chronic progressive diseases in Italy. Methods. 115 subjects (23 with Amyotrophic Lateral Sclerosis – ALS, 30 with Chronic Heart Failure - CHF, 32 with Chronic Kidney Failure – CKF, and 30 with Advanced Cancer – AC) were assessed on health literacy, their right to be informed and meaning of Advance Directives (AD) and of Advance Declaration of Treatment (ADT). Results. 86% of patients claimed the right to know diagnosis and prognosis and to be informed of disease progression. Patients did not know the meaning of invasive therapy (52%) and of aggressive treatment (81%). 72% did not know the meaning of AD and of ADT; 94% believed that AD or ADT could partially or totally guarantee patient’s will to make decisions on end-of-life, with frequency difference on AD or ADT efficiency between CHF and ALS patients (p=.01). Once informed on the definitions of AD (legally binding) and ADT (not legally binding), ALS patients preferred legally binding directives, compared to patients with AC and with CHF (ALS vs CHF p=.005; ALS vs AC p=.001). Patients with CKF would prefer legally binding proposal compared to CHF patients (p=.02). Conclusion. To inform and to guide patients from diagnosis to end-of-life should be an integral part of medical practice.
33
Jhang, Syu, and Allen W. Chiu. "An infertile female delivered a baby after removal of primary renal carcinoid tumor." Open Medicine 16, no. 1 (January 1, 2021): 146–48. http://dx.doi.org/10.1515/med-2020-0408.
Full textAbstract:
Abstract Primary renal carcinoid tumors are exceedingly rare. We report a 37-year-old woman with primary infertility, who was found to have a primary renal carcinoid tumor. She became pregnant and gave birth to a baby after removal of the tumor. This is the first case in the English literature of primary renal carcinoid tumor related with primary infertility.
34
Guo, Fang, Bing Hu, Lei Chen, and Jia Li. "Clinical application of contrast-enhanced ultrasound after percutaneous renal tumor ablation." British Journal of Radiology 92, no. 1103 (November 2019): 20190183. http://dx.doi.org/10.1259/bjr.20190183.
Full textAbstract:
Objective: To evaluate the effectiveness of contrast-enhanced ultrasound (CEUS) in detecting incomplete ablation and local recurrence of renal tumors after percutaneous radiofrequency ablation (RFA). Methods: 31 patients were included for RFA treatment and underwent CEUS examination after RFA, ablation zone and contrast distribution in the ablation area were observed, CEUS images were compared with enhanced CT/MRI images to determine the residual tumors and local recurrence of renal tumors. Results: The average maximum diameters of the tumor and the ablation zone after the first RFA were 32.3 ± 14.7 mm and 35.9 ± 12.2 mm, respectively. A higher rate of complete tumor ablation was achieved if the ablation zone was larger than the primary tumor (p = 0.026). Within 1 month after RFA, contrast-enhanced CT/MRI examinations demonstrated incomplete ablation in 9 of 31 patients (29.0%), while CEUS revealed incomplete ablation in 8 of 31 patients (25.8%). The sensitivity, specificity, positive predictive value and negative predictive value of CEUS in evaluating complete ablation of renal tumors were 88.9%, 100%, 100%, 95.7%, respectively. During the follow-up period, local recurrence was reported in 2 (7.4%) of the 27 patients with complete tumor ablation. Tumor recurrence signs in the two patients were identified by both CEUS and contrast-enhanced CT/MRI. Therefore, both the sensitivity and specificity of CEUS for the evaluation of tumor recurrence were 100%. Conclusion: After percutaneous RFA of renal tumors, the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors is basically the same as that of contrast-enhanced CT/MRI. Advances in knowledge: In this study, we evaluated the effectiveness of CEUS in the follow-up assessment of residual and recurrent tumors after RFA is basically the same as that of contrast-enhanced CT/MRI. Combining multiple follow-up methods may improve the detection rate of residual or recurrent tumors.
35
Xu, Ying-Jin, Song-Hong Wu, Huai-Jun Liu, Pei Niu, Wen-Zeng Shen, Ying-Jie Xu, Xiao-Ping Yin, et al. "Perfusion Computer Tomography Assessment of the Effect of Angiotensin II On Blood Flow Distribution in Rabbits with Intrarenal VX2 Tumors." Cellular Physiology and Biochemistry 47, no. 1 (2018): 97–106. http://dx.doi.org/10.1159/000489752.
Full textAbstract:
Background/Aims: Unlike other organs, which only have one set of capillary network, the renal microvasculature consists of two sets of capillary network series connected by efferent arterioles. Angiotensin II constricts the efferent glomerular artery. Hence, renal tumor blood flow (BF) distribution may be different from tumors in other organs. This study aims to investigate the effects of angiotensin II on the hemodynamics of intrarenal VX2 tumors using perfusion computed tomography(CT). Methods: Twenty-four male New Zealand white rabbits were randomly divided into three groups: groups A (blank controls), group B (negative controls), and group C (angiotensin II-treated animals). Group B and C were established to the model of intrarenal VX2 tumors. Furthermore, perfusion CT of the kidney was performed in each group. Prior to perfusion CT scan in group C, the mean arterial blood was elevated to 150-160 mmHg by angiotensin II. The BF, blood volume (BV), mean transit time (MTT), capillary permeability-surface area product (PS), and relative permeability-surface area product (RPS) of tumors and renal tissues were calculated. Results: Compared with normal renal cortex tissues in group A, the BF, BV and PS values of tumors in group B were significantly lower, MTT was prolonged and RPS increased. Compared with group B, only the RPS of these tumors increased from 83.23 ± 29.17% to 120.94 ± 31.84% by angiotensin II infusion. Angiotensin II significantly increased the RPS value of the renal cortex distant from the tumor (CDT) and the right renal cortex (RRC). Conclusions: Perfusion CT can accurately observe the influence of angiotensin II on normal and tumor BF in kidneys. This clarifies the effect of angiotensin II on intrarenal tumor hemodynamics.
36
Bhindi, Bimal, Robert Houston Thompson, Christine M. Lohse, Ross Mason, Igor Frank, Stephen A. Boorjian, John C. Cheville, and Bradley C. Leibovich. "The probability of indolent versus aggressive histology based on renal tumor size: Implications for surveillance and treatment." Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018): 704. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.704.
Full textAbstract:
704 Background: While the probability of benign versus malignant histology based on renal tumor size has been described, this alone does not sufficiently inform decision-making in the modern era since indolent malignant tumors can be surveilled. Thus, we sought to characterize the probability of indolent versus aggressive histology based on radiographic tumor size. Methods: We evaluated patients who underwent radical or partial nephrectomy at Mayo Clinic for a pT1-2, pNx/0, M0 solid renal tumor between 1990-2010. Pathology was reviewed by one genitourinary pathologist. Benign tumors, low grade (1-2) clear cell and papillary renal cell carcinoma (RCC), and any chromophobe, clear cell papillary, mucinous tubular and spindle cell, SDH-B deficient, and tubulocystic RCC were considered indolent. All other histologies were considered aggressive, as were any malignancies with necrosis or sarcomatoid differentiation. Cancer-specific survival (CSS) was estimated using the Kaplan Meier method. Logistic regression models were used to estimate the probability of malignant and aggressive histology based on tumor size. Sex-stratified analyses were also performed. Results: Of the 2650 patients included, there were 1773 patients with indolent tumors (303 benign; 1470 malignant) and 877 with aggressive tumors. Ten-year CSS was 96% for indolent malignant tumors and 82% for aggressive tumors. The predicted probabilities of any malignant histology and aggressive malignant histology increased with tumor size (Table; 1-7cm point estimates shown). For example, a 3 cm tumor had an 87% probability of malignancy and a 27% probability of being aggressive. For any given tumor size, men had a greater probability of aggressive histology than women. Conclusions: We present tumor size-based estimates of the probability of aggressive histology for renal masses. This information should be useful for patient counseling and treatment decision-making. [Table: see text]
37
Santafé Galvis, Jhonatan Sair, Dilma Alexandra Cruz Arévalo, and Javier Mauricio Salgado Tovar. "Una masa renal poco común en una adolescente – presentación de caso y revisión de la literatura." Revista Urología Colombiana / Colombian Urology Journal 28, no. 04 (March 1, 2019): 321–29. http://dx.doi.org/10.1055/s-0038-1641726.
Full textAbstract:
Introducción Las neoplasias renales en la población pediátrica y adolescente son raras, entre el 6% y el 7% de las masas en pediatría. En adolescentes plantea un desafío clínico importante. Presentan variables manifestaciones sistémicas inespecíficas o cuadros asintomáticos. En la literatura se han identificado el Carcinoma de Células Renales y el Tumor de Wilms como las masas renales más prevalentes en menores de 20 años, el Adenoma Metanéfrico es una entidad muy poco común en esa población. Presentación de caso Adolescente, con dolor en flanco izquierdo y hematuria macroscópica monosintomática, estudios imagenológicos evidencian lesión de aspecto neoplásico renal izquierda, que al complementarse con estudios de inmunohistoquímica resulta en Adenoma Metanéfrico. Se realiza revisión de literatura publicada en las últimas tres décadas al respecto. La paciente es llevada a nefrectomía radical izquierda, y posteriormente el estudio anatomopatológico sugiere Adenoma Metanéfrico, con marcadores de inmunohistoquímica que corroboran el hallazgo. Conclusiones Los tumores renales en adolescentes son raros. Se requiere de alta sospecha clínica, un examen físico meticuloso y el apoyo en imágenes diagnósticas. Generalmente, el estudio histopatológico determina el diagnóstico definitivo, no obstante, cuando persiste la confusión, se recurre a la inmunohistoquímica. El Carcinoma de Células Renales es el más prevalente de los tumores renales en adolescentes, pero existen entidades indistinguibles al estudio imagenológico que plantean un desafío clínico; es el objetivo brindar una herramienta de apoyo en el abordaje del Adenoma metanéfrico e instar al desarrollo de conocimiento sobre una entidad patológica en ese grupo etario que ha sido poco documentado que indudablemente redundará en mejores prácticas e impacto científico, social y económico.
38
Avalos Hernandez, S. R., S. Liu, F. Sameeta, and W. Mneimneh. "Collision Tumor of the Kidney with Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma Components: Report of a Rare Case." American Journal of Clinical Pathology 154, Supplement_1 (October 2020): S64. http://dx.doi.org/10.1093/ajcp/aqaa161.139.
Full textAbstract:
Abstract Introduction/Objective Collision tumors refer to the phenomenon where distinct, well-defined tumor subtypes are present within a single lesion. While this phenomenon has been described in different organs, it has been rarely encountered in renal tumors outside the context of rare tumor susceptibility syndromes. Collision tumors of the kidney may encompass any known benign or malignant renal tumor types. However, a collision tumor of two different renal cell carcinoma (RCC) subtypes is remarkably rare. Methods A 43-year-old male was referred to our institution for the management of a right lower pole renal mass. The right radical nephrectomy specimen revealed a 6.5 x 5.0 x 4.0 cm well circumscribed, yellow-orange and hemorrhagic cortical mass abutting the renal capsule and extending into the renal sinus fat. A grossly distinct 1.5 x 1.4 x 1.2 cm pale, nodular area was demonstrated at the periphery of the tumor. Results Microscopically, the tumor displayed two distinct, neoplastic components within the same mass, without transitional morphology. The majority of the tumor consisted of a nuclear-grade-2 conventional clear cell RCC, while the peripheral nodule represented a type-2 papillary RCC component. Immunostains further supported these findings: The papillary component was strongly and diffusely positive for CK7 and P504S/AMACR with variable EMA and vimentin expression, and negative for CAIX, while the clear cell component was positive for CAIX, EMA and vimentin with only focal and weak staining for CK7 and faint nonspecific P5O4S/AMACR staining. TFE3 Mart1 and HMB45 immunostains were negative in the tumor. Conclusion Collision tumor of the kidney with two distinct RCC subtypes is an exceedingly rare finding. Careful gross examination may be the first clue to identify such lesions, and sampling of all grossly distinct tumor areas is crucial. The identification of collision tumors may have important therapeutic implications, given the difference in pathophysiology and outcome between RCC subtypes.
39
Rioux-Leclercq, Nathalie C., and Jonathan I. Epstein. "Renal Cell Carcinoma With Intratumoral Calcium Oxalate Crystal Deposition in Patients With Acquired Cystic Disease of the Kidney." Archives of Pathology & Laboratory Medicine 127, no. 2 (February 1, 2003): e89-e92. http://dx.doi.org/10.5858/2003-127-e89-rccwic.
Full textAbstract:
Abstract We describe 2 cases of renal cell carcinoma arising in acquired cystic disease of the kidney (ACDK) in patients with end-stage renal disease undergoing hemodialysis for more than 5 years and provide a brief review of the complications of ACDK. In both cases, abundant calcium oxalate crystals were observed within the tumors. Histologically, one of the tumors was a conventional (clear cell) renal cell carcinoma. The other tumor was a bilateral papillary renal cell carcinoma. Both tumors were high-grade carcinomas with extensive oncocytic (acidophilic) features. Also noted within the kidneys were cysts with atypical papillary hyperplasia. The clinicopathologic findings along with review of the literature suggest a relationship between tumor growth and calcium oxalate crystal deposition in patients undergoing hemodialysis with ACDK.
40
Imai, S., Y. Kajihara, S. Nishishita, and T. Hayashi. "Effect of Ethanol Induced Occlusion of the Renal Artery in Rabbit Kidney Implanted with VX2 Carcinoma." Acta Radiologica 30, no. 5 (September 1989): 535–39. http://dx.doi.org/10.1177/028418518903000518.
Full textAbstract:
The effects of injection of absolute ethanol into the renal artery were investigated in 13 rabbit kidneys previously implanted with VX2 carcinoma. Eight rabbits with implanted tumors served as controls. The effects were evaluated by angiography and histology. Three days after implantation, tumors were demonstrated by angiography as relatively hypovascular areas in the subcapsular cortex of the kidneys. Following angiography, absolute ethanol (0.3 ml/kg) was injected into the renal artery. Repeat angiography with barium sulphate was performed after an additional 3 days (10 ethanol treated animals, 2 controls), 10 days (2 treated, 1 control) or 14 days (1 treated, 0 control). In treated animals the tumors were markedly smaller in comparison with those of the control group. The occlusion procedure, however, did not completely eradicate tumor cells. The histologic study of the implanted tumor confirmed the findings previously reported that viable tumor cells still remained in the peripheral portions of infarcted areas. This study demonstrated the beneficial, though not curative, short-term effects of transcatheter renal artery treatment with absolute ethanol in malignant renal tumors.
41
Salehipour, Mehdi, Amir Ahmad Mostaghni, Bita Geramizadeh, Alireza Makarem, and Alireza Rezvani. "Constipation, the sole presentation of primary renal carcinoid tumor: A case report." Rare Tumors 11 (January 2019): 203636131987891. http://dx.doi.org/10.1177/2036361319878915.
Full textAbstract:
Primary renal carcinoid tumors are quite rare. The pathogenesis of these tumors is unknown due to lack of enterochromaffin cells in the kidney. Because of nonspecific clinical manifestations and radiologic features, they are commonly misdiagnosed. Hence, Primary renal carcinoid tumors should be considered in differential diagnosis of any renal mass. In the present case, a 26-year-old woman was presented with a renal mass and constipation. After partial nephrectomy, diagnosis of carcinoid tumor was confirmed.
42
Cesar, Bruno Nogueira, Nilo Eduardo Delboni Nunes, Maria Amelia Aguiar Hazin, Renato Demarchi Foresto, Gianna Mastroianni Kirsztajn, and Marcelino Souza Durao Junior. "Spontaneous clinical tumor lysis syndrome in solid renal tumor: first case report in non-metastatic renal carcinoma." Journal of Onco-Nephrology 4, no. 3 (August 10, 2020): 124–27. http://dx.doi.org/10.1177/2399369320945718.
Full textAbstract:
Spontaneous tumor lysis syndrome is a rare emergency in onco-nephrology that results from extensive cancer cell lysis independent of antitumoral therapy. It is common among hematological tumors and can be rarely seen with solid tumors. In medical literature, there is only one case report with spontaneous tumor lysis syndrome in renal cell carcinoma and it was associated with metastases. To the best of our knowledge, this is the first report of spontaneous tumor lysis syndrome in non-metastatic renal cell carcinoma.
43
Amornporncharoen, Treerat, Nattapong Wongwattanasatien, Vorapot Choonhaklai, Viroj Chittchang, Somkiet Pumpaisanchai, Tanet Thaidumrong, Sermsin Sindhubodee, Chawawat Kosrisirikul, and Matchima Huabkong. "Correlation between hydronephrosis, tumor diameter, and pathologic T stage of upper tract transitional cell carcinoma after nephroureterectomy." Insight Urology 41, no. 2 (December 8, 2020): 9–16. http://dx.doi.org/10.52786/a.2.
Full textAbstract:
Objective: To evaluate the correlation between hydronephrosis, tumor diameter, and pT stage of upper tract transitional cell carcinoma. Material and Method: From October 2004 to December 2018, the medical records of 98 patients in Rajavithi Hospital who were diagnosed with renal pelvic (47 patients) and ureteral (51 patients) transitional cell carcinoma and treated with nephroureterectomy were retrospectively reviewed. Patient demographics, degree of hydronephrosis, tumor diameter from computed tomography, and pathologic report were collected. Data were analyzed to determine correlations. Results: In renal pelvic tumor, higher degree of hydronephrosis correlated with higher pT stage (p=0.022) but no significant difference was shown in ureteral tumor (p=0.352). For tumor diameter in both renal pelvis and ureter, there were no correlations with pT stage (p=0.128 and p=0.625). For tumor location, higher pT stage was more common in renal pelvic tumors (p=0.001) and high tumor grade correlated with high pT stage (p=0.037). Conclusion: In this study, there was significant correlation between the preoperative degree of hydronephrosis and pT stage in renal pelvic transitional cell carcinomas; however, none was found in ureteric tumors. The reason may be that smaller ureteric lumen caused early symptoms, which concerned patients.
44
Hernández Alcaraz, David, Begoña Beneto-Alducin, and Pedro Morales-Jiménez. "Metástasis atipicas del tumor renal." Revista Mexicana de Urología 79, no. 1 (April 8, 2019): 1–7. http://dx.doi.org/10.48193/rmu.v79i1.389.
Full textAbstract:
Introducción: El objetivo del presente trabajo es presentar tres casos clínicos con presentaciones poco frecuentes de metástasis de carcinoma renal.
Descripción de los casos: El primer caso es una mujer en la que se objetivan metástasis en el tiroides tras una tiroidectomía. El resto del estudio de extensión era negativo y no necesitó de tratamiento adyuvante. El segundo caso es el de una mujer que acudió a urgencias por retención urinaria secundaria a una metástasis uretral de un carcinoma renal, sin metástasis a otros niveles. El tercer caso es de un varón con una recidiva de un carcinoma renal de tipo papilar en la mucosa vesical, asociado a metástasis pulmonares.
Discusión: El 34% de las metástasis en tiroides son de origen renal. La uretra es un sitio poco frecuente de metástasis. En líneas generales, las metástasis renales en vejiga indican mal pronóstico, únicamente existen 56 casos descritos en la literatura. El tratamiento de elección ante lesiones resecables es la extirpación quirúrgica, reservando la terapia antiangiogénica para las que no lo son.
Conclusiones: Las metástasis tiroideas, vesicales y en uretra son sitios poco frecuentes de metástasis de cáncer renal. Suelen indicar fases avanzadas de la enfermedad y su tratamiento, si son resecables, consiste en su extirpación quirúrgica.
45
Hernández Alcaraz, David, Begoña Beneto-Alducin, and Pedro Morales-Jiménez. "Metástasis atipicas del tumor renal." Revista Mexicana de Urología 79, no. 1 (April 8, 2019): 1–7. http://dx.doi.org/10.48193/revistamexicanadeurologa.v79i1.389.
Full textAbstract:
Introducción: El objetivo del presente trabajo es presentar tres casos clínicos con presentaciones poco frecuentes de metástasis de carcinoma renal.
Descripción de los casos: El primer caso es una mujer en la que se objetivan metástasis en el tiroides tras una tiroidectomía. El resto del estudio de extensión era negativo y no necesitó de tratamiento adyuvante. El segundo caso es el de una mujer que acudió a urgencias por retención urinaria secundaria a una metástasis uretral de un carcinoma renal, sin metástasis a otros niveles. El tercer caso es de un varón con una recidiva de un carcinoma renal de tipo papilar en la mucosa vesical, asociado a metástasis pulmonares.
Discusión: El 34% de las metástasis en tiroides son de origen renal. La uretra es un sitio poco frecuente de metástasis. En líneas generales, las metástasis renales en vejiga indican mal pronóstico, únicamente existen 56 casos descritos en la literatura. El tratamiento de elección ante lesiones resecables es la extirpación quirúrgica, reservando la terapia antiangiogénica para las que no lo son.
Conclusiones: Las metástasis tiroideas, vesicales y en uretra son sitios poco frecuentes de metástasis de cáncer renal. Suelen indicar fases avanzadas de la enfermedad y su tratamiento, si son resecables, consiste en su extirpación quirúrgica.
46
Bing, Zhanyong, and John E. Tomaszewski. "Clear Cell Papillary Renal Cell Carcinoma in the Bilateral Native Kidneys after 2 Years of Renal Transplantation: Report of a Case and Review of the Literature." Case Reports in Transplantation 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/387645.
Full textAbstract:
Renal transplantation increases the probability of malignant tumors by about 2–4-fold overall with a much higher rate for renal epithelial malignancy. Renal tumors in renal transplant recipients are commonly conventional clear cell or papillary renal cell carcinoma. Clear cell papillary renal cell carcinoma is a recently described unique renal epithelial neoplasm with scant eosinophilic or moderate amount of clear cytoplasm and pyknotic small nuclei oriented commonly toward the apical surfaces. No such tumor has been reported in renal transplant recipients. In this paper, we describe a clear cell papillary renal cell carcinoma involving bilateral native kidneys in a patient who had received a renal transplant 2 years earlier. Clear cell papillary renal cell carcinoma commonly presents with low pathologic stage and lower Fuhrman grade and is clinically indolent. Additional cases are needed to evaluate the clinical behavior of this type of tumor in renal transplant recipients.
47
Ortiz Herrera, Marco Antonio, and Mario Roberto Morales Ruíz. "Caso Interesante Revista. “Carcinoma Renal de Células Claras Contralateral Metacrónico. Nefrectomía Parcial”." Revista Guatemalteca de Urología 6, no. 1 (December 31, 2018): 36–38. http://dx.doi.org/10.54212/27068048.v6i1.75.
Full textAbstract:
Se presenta un caso de carcinoma renal contralateral metacrónico. Paciente de 57 años, con antecedente de nefrectomía radical izquierda por carcinoma renal de células claras, quien presenta un nuevo tumor renal derecho de 3 cms de diámetro; por lo que se realiza nefrectomía parcial derecha. El diagnóstico patológico reporta Carcinoma de Células Renales, Células claras.
48
Algaba, F. "Renal Adenomas: Pathological Differential Diagnosis with Malignant Tumors." Advances in Urology 2008 (2008): 1–4. http://dx.doi.org/10.1155/2008/974848.
Full textAbstract:
The renal adenomas can be confused by imaging diagnosis with malignant renal tumors, but there are also real biological dilemmas to determine their behavior. The consensus decisions are the following. (1) The adenoma of clear cells is not accepted, instead it is considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness. (2) Among the papillary neoplasms the WHO 2004 renal cell tumors classification are considered as papillary adenomas tumors with a maximum diameter of 5 mm and may represent a continuum biological process to papillary renal cell carcinoma. The papillary adenomas associated with End-kidney and/or acquired cystic disease may have a different pathogenesis. (3) To consider a tumor as an oncocytoma the size is not important, only the cytological features, microscopic, ultrastructural, and immunohistochemically can help, but some chromosomal observations introduce some questions about its relation with the chromophobe renal cell carcinoma. (4) Finally, the metanephric adenoma, a tumor with some morphological similarity with the nephroblastoma must be considered in the renal adenomas diagnosis.
49
Karavaeva, E. A., T. E. Taranushenko, A. V. Morgun, M. V. Borisova, T. G. Kadricheva, T. I. Bulava, N. A. Gonchar, and E. A. Guseynova. "Renal tumors in children and adolescents (primary diagnostics based on a pilot study)." Russian Journal of Woman and Child Health 4, no. 2 (2021): 162–67. http://dx.doi.org/10.32364/2618-8430-2021-4-2-162-167.
Full textAbstract:
Aim: to assess the rate of detection and epidemiology of renal tumors in children of the Krasnoyarsk Krai and to specify some tumor characteristics during primary diagnostics. Patients and Methods: retrospective exploratory (pilot) dynamic single-center study was conducted. A group of 46 children and adolescents with renal tumors who were admitted to the Department of Hematological Malignancies for examinations and treatment in 2011–2019. All data were obtained from hospital register. Results: renal tumors account for 6.4% of hematological malignancies first diagnosed in children. 9-year primary incidence of renal tumors in children was, on average, 0.87 per 100,000 children, alternating between the increase and decrease in the detection rate. Renal tumors rank 4th among hematological malignancies in the Krasnoyarsk Krai children. The mean age was 4.1±0.5 years. No gender differences were revealed. In a pre-hospital setting, renal tumors were suspected in 24 children (52%). The most common complaints were abdominal pains (34 patients, 74%) and enlarged abdomen (30 patients, 65%). Most renal tumors (40 out of 46) were nephroblastoma as demonstrated by histology. The distribution by prognostic risk (the likelihood of recurrence and/or other unfavorable outcome) has shown that most patients have intermed iate (n=25, 54%) or high (n=19, 42%) risk. Conclusions: our findings illustrate that children with renal tumors require more attention of pediatricians in a pre-hospital setting (cancer vigilance about abdominal pains and enlarged abdomen in children) to reduce the time to diagnosis and to increase the use of renal ultrasound during checkups or in suspicious renal tumors. KEYWORDS: nephroblastoma, Wilms tumor, renal tumors, children, epidemiology, prevalence, primary diagnostics. FOR CITATION: Karavaeva E.A., Taranushenko T.E., Morgun A.V. et al. Renal tumors in children and adolescents (primary diagnostics based on a pilot study) . Russian Journal of Woman and Child Health. 2021;4(2):162–167. DOI: 10.32364/2618-8430-2021-4-2-162-167.
50
Shin, Toshitaka, Tomoko Kan, Fuminori Sato, and Hiromitsu Mimata. "Tumor-to-Tumor Metastasis to Chromophobe Renal Cell Carcinoma: A First Report." Case Reports in Urology 2011 (2011): 1–3. http://dx.doi.org/10.1155/2011/520839.
Full textAbstract:
Tumor-to-tumor metastasis is a rare phenomenon. From our review of the international literature, around 150 cases have been reported since it was first documented by Campbel in 1868. Renal clear cell carcinoma is well known to be the most common recipient of tumor-to-tumor metastasis in all tumors. However, renal chromophobe cell carcinoma has not been reported to be a recipient. Here, we report a first case of colorectal carcinoma metastatic to chromophobe renal cell carcinoma.